The Phase IIa study will assess the efficacy of CTH120 as an innovative therapy in adults with FXS, the most common form of inherited intellectual disability without a specific treatment.
Philips’ AI-enabled MR imaging and Quibim’s AI-enabled image analysis software aims to help clinicians deliver faster, easier prostate cancer care, to help mitigate staff shortages and lower the cost of care
Nanobots Therapeutics specializes in the development of biocompatible nanorobots capable of delivering drugs to difficult-to-treat tumors more efficiently and safely. This revolutionary technology is expected to significantly improve the effectiveness and safety of current and future medical treatments.
Securing the CE mark as a class IIb device, sets Quibim as a leader in the market, making QP-Prostate® one of the first AI products approved by the new MDR regulation.
Prous Institute for Biomedical Research is to present the 2022 Prous Institute – Overton & Meyer Award to Professor Alessio Ciulli, at the XXVII International Symposium on Medicinal Chemistry organized by the European Federation of Medicinal Chemistry (EFMC).
Both companies will collaborate to offer drug discovery and development services and to advance a common internal pipeline of drug development projects.
Licensing agreement grants Oculis exclusive global rights to develop and commercialize ACT-01, a potentially disease modifying therapy to protect and prevent damage to the optic nerve and retina.
The funding has been obtained through the Neotec programme, managed by the Spanish Ministry of Science and Innovation Centre for the Development of Industrial Technology (CDTI), in its 2021 call for projects.
CTH120, designed using artificial intelligence techniques, will start Phase I in 2022. CTH120 designation as orphan drug validates and empowers Connecta Therapeutics's strategy in neurodevelopmental diseases
